Oslo universitetssykehus HF

Institute presentation

Oslo universitetssykehus HF (OUS) has a nationwide responsibility for a number of national and multi-regional assignments and has several national centers of competence. OUS is responsible for approximately 50 percent of all medical and healthcare research conducted at Norwegian hospitals and is a significant role player within the education of a large variety of health care personnel. The hospital is Scandinavia’s largest and each year carries out more than 1.2 million patient treatments. The aim of the hospital is to create a well functioning and efficient local hospital, to strengthen highly specialized medicine, conduct research and provide education and innovation on international levels.

The Project Leaders have long experience with health-economic evaluations. Prof Berge (until 2019) and Dr. Aamodt were responsible for the health-economic evaluation of thrombolytic treatment for stroke in the UK, commissioned by the NHS R&D Health Technology Assessment Programme, and is currently involved in the cost-/utility-analyses of the Scandinavian Candesartan Acute Stroke Trial (SCAST, Lancet 2011) and the Third International Stroke Trial (IST-3). Prof Melberg is Leader of the OUS research group in economic evaluation, and has been involved in a number of health-economic evaluations commisioned by the Norwegian Government, Ministry of Finance, Ministry of Health, and the Norwegian Directorate of Health. He is currently partner in a number of international collaborations, including a project led by Prof Zeke Emmanuel (University of Pennsylvania, USA), and the Addictions and Lifestyle in Contemporary Europe – Reframing Addictions Project (ALICE-RAP), financed by the EU 7th Framework Programme. 

Main tasks attributed in the project:

OUS was responsible for WP 5 (Health Economics) in the project.